<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; payments</title>
	<atom:link href="http://www.tapanray.in/tag/payments/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pills and Payments: India&#8217;s Unethical Drug Marketing Problem</title>
		<link>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pills-and-payments-indias-unethical-drug-marketing-problem</link>
		<comments>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/#comments</comments>
		<pubDate>Fri, 27 Jun 2025 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[payments]]></category>
		<category><![CDATA[pills]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unethical]]></category>
		<category><![CDATA[Vikshit]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10925</guid>
		<description><![CDATA[The recent exposé by The Economic Times, titled &#8220;Rx Name Unethical practitioners,&#8221; published on June 19, 2025, which brought to light allegations of a prominent global pharmaceutical company sponsoring extravagant foreign trips for doctors in violation of ethical codes, serves as &#8230; <a href="http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will mandatory disclosure of ‘payments to physicians’ by the pharmaceutical companies be an overall part of “Healthcare reform process” in the US and what about India?</title>
		<link>http://www.tapanray.in/will-mandatory-disclosure-of-payments-to-physicians-by-the-pharmaceutical-companies-be-an-overall-part-of-healthcare-reform-process-in-the-us-and-what-about-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-mandatory-disclosure-of-payments-to-physicians-by-the-pharmaceutical-companies-be-an-overall-part-of-healthcare-reform-process-in-the-us-and-what-about-india</link>
		<comments>http://www.tapanray.in/will-mandatory-disclosure-of-payments-to-physicians-by-the-pharmaceutical-companies-be-an-overall-part-of-healthcare-reform-process-in-the-us-and-what-about-india/#comments</comments>
		<pubDate>Thu, 12 Nov 2009 01:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[about]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[overall]]></category>
		<category><![CDATA[part]]></category>
		<category><![CDATA[payments]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[what]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=727</guid>
		<description><![CDATA[The brief Scenario in India: In India over 20, 000 pharmaceutical companies of varying size and scale of operations are currently operating. It is alleged that lack of regulatory scrutiny is prompting many of these companies to adapt to ‘free-for-all’ &#8230; <a href="http://www.tapanray.in/will-mandatory-disclosure-of-payments-to-physicians-by-the-pharmaceutical-companies-be-an-overall-part-of-healthcare-reform-process-in-the-us-and-what-about-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-mandatory-disclosure-of-payments-to-physicians-by-the-pharmaceutical-companies-be-an-overall-part-of-healthcare-reform-process-in-the-us-and-what-about-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ethical Pharmaceutical Marketing Practices: &#8216;Self-Regulation&#8217;&#8230;&#8217;Voluntary Physician Payments Disclosure&#8217;&#8230;What&#8217;s next?</title>
		<link>http://www.tapanray.in/ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next</link>
		<comments>http://www.tapanray.in/ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next/#comments</comments>
		<pubDate>Mon, 09 Nov 2009 00:30:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[payments]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=730</guid>
		<description><![CDATA[Over a period of time, many stakeholders of the pharmaceutical industry and the public at large have been raising the issue of physicians being influenced in their prescription decisions by various types of payments made to them by the pharmaceutical &#8230; <a href="http://www.tapanray.in/ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
